$0.38
2.90% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US92243A2006
Symbol
VXRT

Vaxart, Inc. Stock price

$0.38
-0.05 11.63% 1M
-0.34 47.54% 6M
-0.28 42.61% YTD
-0.20 34.99% 1Y
-3.78 90.87% 3Y
-8.82 95.87% 5Y
-25.91 98.55% 10Y
-361.19 99.89% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.01 2.90%
ISIN
US92243A2006
Symbol
VXRT
Industry

Key metrics

Basic
Market capitalization
$89.4m
Enterprise Value
$51.2m
Net debt
positive
Cash
$41.9m
Shares outstanding
228.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.9 | 4.1
EV/Sales
1.1 | 2.3
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
35.4%
Return on Equity
-113.6%
ROCE
-95.2%
ROIC
-169.2%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$47.4m | $22.0m
EBITDA
$-48.2m | -
EBIT
$-57.2m | $-71.9m
Net Income
$-58.1m | $-65.3m
Free Cash Flow
$-33.7m
Growth (TTM | estimate)
Revenue
433.2% | -23.2%
EBITDA
34.0% | -
EBIT
30.2% | -8.5%
Net Income
28.9% | 2.4%
Free Cash Flow
50.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-101.8% | -
EBIT
-120.6%
Net
-122.6% | -296.6%
Free Cash Flow
-71.2%
More
EPS
$-0.3
FCF per Share
$-0.1
Short interest
9.4%
Employees
105
Rev per Employee
$270.0k
Show more

Is Vaxart, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Vaxart, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vaxart, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Vaxart, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Vaxart, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
47 47
433% 433%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
20% 20%
39%
- Research and Development Expense 86 86
27% 27%
181%
-48 -48
34% 34%
-102%
- Depreciation and Amortization 8.92 8.92
2% 2%
19%
EBIT (Operating Income) EBIT -57 -57
30% 30%
-121%
Net Profit -58 -58
29% 29%
-123%

In millions USD.

Don't miss a Thing! We will send you all news about Vaxart, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxart, Inc. Stock News

Neutral
GlobeNewsWire
19 days ago
- Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings Panel Meeting Scheduled on August 14, 2025 - SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology compan...
Neutral
GlobeNewsWire
2 months ago
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Preliminary results from the Annual Meeting in...
Neutral
GlobeNewsWire
2 months ago
- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection against infection -
More Vaxart, Inc. News

Company Profile

Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.

Head office United States
CEO Steven Lo
Employees 105
Founded 2004
Website vaxart.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today